Dianthus Therapeutics, Inc.
DNTH
Rangering i aksjer
#3819
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aksjekurs
$78.25
Markedsverdi
$4.38B
Endring (1 dag)
4.98%
Endring (1 år)
117.36%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
Historikk for aksjesplitt for Dianthus Therapeutics, Inc. (DNTH)
Aksjen Dianthus Therapeutics, Inc. (symbol: DNTH) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Sep 12, 2023.
Én DNTH-aksje kjøpt før Sep 12, 2023 tilsvarer i dag 0.0625 DNTH-aksjer.
Den nyeste splittelsen skjedde Sep 12, 2023.
Én DNTH-aksje kjøpt før Sep 12, 2023 tilsvarer i dag 0.0625 DNTH-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| 2023-09-12 | 1:16 | x0.0625 | x0.0625 |
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
